NK cells are critical for innate immunity–mediated protection. The main roles of NK cells rely on their cytotoxic functions or depend on the tuning of Th1 adaptive immunity by IFN-γ. However, the precise influence of inflammatory cytokines on NK cell and CD4 T lymphocyte interactions was never investigated. In this study, we provide evidence that IL-21, a cytokine produced during chronic inflammation or infectious diseases, promotes the differentiation of a specific subset of NK cells coexpressing CD86 and HLA-DR and lacking NKp44. More importantly, IL-21–propagated HLA-DR+ NK cells produce macrophage migration inhibitory factor and provide costimulatory signaling during naive CD4+ T cell priming inducing the differentiation of uncommitted central memory T cells. Central memory T cells expanded in the presence of HLA-DR+ NK cells are CXCR3+CCR6−CCR4−CXCR5− and produce IL-2, as well as low levels of TNF-α. Costimulation of CD4+ T cells by HLA-DR+ NK cells prevents the acquisition of effector memory phenotype induced by IL-2. Moreover, we identified this population of NK HLA-DR+ macrophage migration inhibitory factor+ cells in inflammatory human appendix. Collectively, these results demonstrate a novel function for IL-21 in tuning NK and CD4+ T cell interactions promoting a specific expansion of central memory lymphocytes.
Aberrant expression of the oncogene SALL4 is associated with stemness, a more aggressive cancer phenotype, and reduced patient survival in various tumor types, making SALL4 a potential target for cancer immunotherapy. We conducted a transcriptional analysis of SALL4 expression in colorectal cancer tissues and demonstrated that SALL4 was overexpressed in primary tumors and paired liver metastases. Then, we identified the SALL4-derived S9V peptide as a naturally processed peptide that induced specific CD8+ T-cell responses from the peripheral blood of patients with gastrointestinal cancer, whereas no responses were observed in the peripheral blood of healthy donors. Thereafter, we isolated an SALL4-specific T-cell receptor (TCR) that recognized this peptide in the most common HLA molecule in the Caucasian population, HLA-A2, and used this to develop TCR-engineered T cells. In vitro analysis showed that SALL4 TCR–redirected primary CD8+ T cells exhibited cytotoxic effects against SALL4-expressing tumor cells and produced effector cytokines. In vivo, SALL4-TCR T cells significantly reduced tumor growth and improved the survival of tumor-bearing mice. Moreover, SALL4-TCR T cells displayed no toxicity against hematopoietic stem cells. Thus, we conclude that T cells engineered to express a SALL4-specific TCR have the potential to be effective as immunotherapy for solid cancers and pave the way for further clinical development.
SALL4-TCR T cells do not recognize human hematopoietic stem cells CD34+ in vivo. (A) Schematic outlining the experimental procedure of adoptive T cell transfer in hNSG mice. hNSG mice were engrafted IV with 107 Mock (n=9) or SALL4-TCR transduced T cells (n=10) or not (n=8). Seven days after injection, mice were sacrificed and BM were collected. Blood samples were harvested at day 0 before T cells injection and at day 7 following T cell injection. (B) Flow cytometry gating strategy in BM (left) and in the blood samples (right). (left) HSC were determined by the expression of CD34 and CD38 among human CD45 cells. Dendritic cell (DC), in pink, were determined by the medium expression on CD33 and medium expression of CD123, HLA-DR and CD303. Monocytes, in blue, were determined by the high expression of CD33, medium expression on HLA-DR, CD123 and CD303. (right) The percentage of humanization is determined by the ratio mCD45/hCD45. Monocytes were selected from human cells (hCD45+) based on the expression of CD33 and CD14. (C) and (D) Flow cytometry analyses of HSC and myeloid-derived differentiated cells in BM (C) and monocytes in blood (D) among hCD45 cells.
SALL4 induction in cancer cell by 5-azacytidine modulates SALL4-TCR T cells activation. (A) Expression of SALL4 detected by qRT-PCR (top) and Western blotting (bottom) (Sall4 Antibody (G-3): sc-166033 Santa Cruz) for MDA-MB231 treated with 5-azacytidine (5-aza) (2µM) for 72h and 6 days. (B) Degranulation (CD107a) stainings assessed by flow cytometry comparing Mock and SALL4-TCR T cells for their SALL4 reactivity upon coculture with MDA-MB231 treated 72h and 6 Days with 5-Aza. T cells were cocultured for 5h at E:T ratio 1:50 for n=3 different HDs, mean ±SEM. Anti-HLA-A2 (BB7.2) were used for specific reactivity controls. Statistics were calculated using ANOVA test, *p<0.05, ***p<0.001. (C) Relative mRNA expression levels of SALL4 in cancer cell lines pretreated or not with 5-aza (2µM) for 72h. (D) Intracellular TNF-α staining assessed by flow cytometry analysis comparing Mock and SALL4-TCR T cells for their SALL4 reactivity upon coculture with cancer cell lines treated 48h before the coculture with IFN-γ (200UI/mL) and 72 h with 5-aza (2µM) or not. T cells were cocultured for 16h at E:T ratio 1:20. (E) Anti-MHC-I (W6/32) or isotype antibody were used for specific reactivity controls. Cell lines were not treated prior the coculture. HeLa, A2780 and HUH-7 were transduced to express HLA-A2.
S9V is an immunogenic peptide in humanized mouse model. (A) The immunogenicity of SALL4-derived peptides (A9V, T9K, V9L, L10L, K9Y and S9V) has been analyzed in vivo in HLA-DRB1*0101/HLA-A*0201 (A2/DR1) humanized mouse model. These are "Knock Out" mice for murine MHC-I and II molecules. Hockpad immunization starts on day 0 with an injection of 100µg of each peptides and with 50µg of an adjuvant, CpG. Two further injections were performed on day 7 and day 14 with 50µg of each peptides and with 30µg of CpG. The mice were sacrificed on day 16 to harvest the popliteal lymph nodes and SALL4-specific immune responses were analyzed. (B) Representation of ex vivo T cell responses analyzed by murine IFN-γ ELISpot assay for one S9V positive mice. (C) Median intensities and (D) frequencies of SALL4-specific immune responses were assessed by IFN-γ ELISpot assay in popliteal lymph nodes of humanized mouse after hockpad immunization. Responses were considered positive when the IFN-γ spot number was ≥10 and the ratio was 2-fold above the background. Only the positive intensities of specific immune responses were indicated.